Premium
MRI for development of disease‐modifying osteoarthritis drugs
Author(s) -
Burstein Deborah
Publication year - 2006
Publication title -
nmr in biomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 114
eISSN - 1099-1492
pISSN - 0952-3480
DOI - 10.1002/nbm.1071
Subject(s) - osteoarthritis , cartilage , drug development , modality (human–computer interaction) , computer science , medicine , process (computing) , magnetic resonance imaging , medical physics , radiology , bioinformatics , pathology , drug , artificial intelligence , biology , anatomy , pharmacology , alternative medicine , operating system
MRI has advantages as an imaging modality for drug development through its potential to provide information regarding localized morphological parameters, in addition to metrics of the structural and molecular state of cartilage. These metrics have the potential to provide earlier indications of pathology and may progress more rapidly than radiographic measures. These combined scans of localized morphology and matrix parameters will most likely provide a fuller assessment of cartilage state and will improve the cost and practicality of an overall evaluation of cartilage status by MRI. In the first part of this review, the relevant parameters are presented in terms of the information content they might provide in the drug development process. In the second part, applications of the MRI parameters in preclinical and clinical drug development are presented. Copyright © 2006 John Wiley & Sons, Ltd.